Evusheld No Longer Authorized for COVID Prevention
Tixagevimab-cilgavimab (Evusheld) lost authorization for use in the U.S. to prevent COVID-19 until further notice, the FDA announced on Thursday. The agency revised the monoclonal antibody cocktail’s emergency use authorization (EUA) to limit its use to only periods when SARS-CoV-2 variants susceptible to it account for at least 9% of COVID-19 cases nationally. “Data show […]